US6472147B1
(en)
*
|
1999-05-25 |
2002-10-29 |
The Scripps Research Institute |
Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
|
US7037706B1
(en)
|
1999-09-29 |
2006-05-02 |
Xenoport, Inc. |
Compounds displayed on replicable genetic packages and methods of using same
|
EP1224327A4
(de)
*
|
1999-09-29 |
2004-09-08 |
Xenoport Inc |
Zusammensetzungen auf genetisch replizierbaren produkten und methoden zu deren verwendung
|
JP5149476B2
(ja)
*
|
2000-04-17 |
2013-02-20 |
ダイアックス コーポレイション |
ペプチドの多種多様なファミリーのメンバーとしての、遺伝的パッケージの提示ライブラリーを構築する方法
|
US8288322B2
(en)
|
2000-04-17 |
2012-10-16 |
Dyax Corp. |
Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
|
CA2784251A1
(en)
|
2000-12-18 |
2002-08-08 |
Dyax Corp. |
Focused libraries of genetic packages
|
AU2002258602A1
(en)
|
2001-03-21 |
2002-10-08 |
Xenoport, Inc. |
Compounds displayed on icosahedral phage and methods of using same
|
US6833441B2
(en)
|
2001-08-01 |
2004-12-21 |
Abmaxis, Inc. |
Compositions and methods for generating chimeric heteromultimers
|
US7202045B2
(en)
*
|
2001-09-19 |
2007-04-10 |
Regents Of The University Of Michigan |
Detection and treatment of cancers of the lung
|
US7175983B2
(en)
*
|
2001-11-02 |
2007-02-13 |
Abmaxis, Inc. |
Adapter-directed display systems
|
CA2505849C
(en)
*
|
2002-07-30 |
2013-11-05 |
Morphosys Ip Gmbh |
Novel tricistronic vectors and uses therefor
|
US20040067532A1
(en)
*
|
2002-08-12 |
2004-04-08 |
Genetastix Corporation |
High throughput generation and affinity maturation of humanized antibody
|
DK1558643T3
(da)
|
2002-11-09 |
2009-09-07 |
Immunocore Ltd |
Cellereceptorpr sentation
|
ES2362424T3
(es)
|
2003-01-07 |
2011-07-05 |
Dyax Corporation |
Biblioteca del dominio kunitz.
|
NZ548990A
(en)
|
2004-02-06 |
2009-06-26 |
Morphosys Ag |
Anti-CD38 human antibodies and uses therefor
|
CA2555185C
(en)
|
2004-02-06 |
2020-03-24 |
Morphosys Ag |
Anti-cd38 human antibodies and uses therefor
|
US9200061B2
(en)
|
2004-02-06 |
2015-12-01 |
Morpho Sys AG |
Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
|
EP1855723B1
(de)
|
2005-03-08 |
2013-05-22 |
Ramot at Tel-Aviv University Ltd. |
Zielgerichtete arzneistofftragende bakteriophagen
|
BRPI0610796B8
(pt)
|
2005-05-18 |
2021-05-25 |
Morphosys Ag |
anticorpo humano ou humanizado isolado, ou um fragmento fab ou scfv do mesmo, sequência de ácidos nucleicos, vetor, e, uso de um anticorpo
|
US8114964B2
(en)
|
2005-05-19 |
2012-02-14 |
Centocor, Inc. |
Anti-MCP-1 antibodies, compositions, methods and uses
|
AR053489A1
(es)
|
2005-05-24 |
2007-05-09 |
Morphosys Ag |
Generacion perfilado de anticuerpos terapeuticos totalmente derivados de hucal gold humanos especificos para cd38 humano
|
CN103554260A
(zh)
|
2005-10-12 |
2014-02-05 |
莫佛塞斯公司 |
特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定
|
DE502005009389D1
(de)
|
2005-11-09 |
2010-05-20 |
Morphosys Ag |
Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern
|
DOP2006000277A
(es)
|
2005-12-12 |
2007-08-31 |
Bayer Pharmaceuticals Corp |
Anticuerpos anti mn y métodos para su utilización
|
KR20080080653A
(ko)
*
|
2005-12-20 |
2008-09-04 |
모르포시스 아게 |
Hcdr3 영역들의 신규한 집합 및 그 사용
|
KR20080113218A
(ko)
|
2006-03-30 |
2008-12-29 |
노파르티스 아게 |
c―Met의 항체에 대한 사용 방법 및 조성물
|
AU2007248559A1
(en)
|
2006-05-04 |
2007-11-15 |
Abmaxis Inc. |
Cross-species and multi-species display systems
|
ES2372709T3
(es)
|
2006-07-05 |
2012-01-25 |
Catalyst Biosciences, Inc. |
Procedimientos de cribado de proteasas y proteasas identificadas por los mismos.
|
US8759087B2
(en)
|
2006-12-12 |
2014-06-24 |
Morpho Sys AG |
Internalization
|
KR20100089816A
(ko)
*
|
2007-08-21 |
2010-08-12 |
모르포시스 아게 |
이황화 결합을 형성하기 위한 개선된 방법
|
RU2525133C2
(ru)
|
2007-08-30 |
2014-08-10 |
Дайити Санкио Компани, Лимитед |
Антитело к epha2
|
CA2697193C
(en)
*
|
2007-09-14 |
2017-06-06 |
Adimab, Inc. |
Rationally designed, synthetic antibody libraries and uses therefor
|
US8877688B2
(en)
|
2007-09-14 |
2014-11-04 |
Adimab, Llc |
Rationally designed, synthetic antibody libraries and uses therefor
|
TWI489993B
(zh)
|
2007-10-12 |
2015-07-01 |
Novartis Ag |
骨硬化素(sclerostin)抗體組合物及使用方法
|
US9023351B2
(en)
|
2007-11-26 |
2015-05-05 |
Bayer Intellectual Property Gmbh |
Anti-mesothelin antibodies and uses thereof
|
DK2474613T3
(da)
|
2008-02-05 |
2014-10-06 |
Bicycle Therapeutics Ltd |
Fremgangsmåder og sammensætninger
|
US9873957B2
(en)
|
2008-03-13 |
2018-01-23 |
Dyax Corp. |
Libraries of genetic packages comprising novel HC CDR3 designs
|
US8703921B2
(en)
|
2008-04-15 |
2014-04-22 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Compositions and methods for delivering inhibitory oligonucleotides
|
US10485879B2
(en)
|
2008-04-15 |
2019-11-26 |
Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health |
Plasma cell cytokine vehicle containing fusion proteins for targeted introduction of siRNA into cells and tissues
|
JP5780951B2
(ja)
*
|
2008-04-24 |
2015-09-16 |
ダイアックス コーポレーション |
新規のhccdr1、cdr2、およびcdr3設計、ならびに新規のlccdr1、cdr2、およびcdr3設計を含む、遺伝子パッケージのライブラリ
|
MY159396A
(en)
|
2008-08-05 |
2016-12-30 |
Novartis Ag |
Compositions and methods for antibodies targeting complement protein c5
|
EP3199630B1
(de)
|
2008-09-05 |
2019-05-08 |
President and Fellows of Harvard College |
Kontinuierliche gerichtete evolution von proteinen und nukleinsäuren
|
WO2010079189A1
(en)
|
2009-01-09 |
2010-07-15 |
Morphosys Ag |
Display vectors and methods and uses thereof
|
TWI480050B
(zh)
|
2009-02-10 |
2015-04-11 |
Daiichi Sankyo Co Ltd |
抗-mst1r抗體及其用途
|
AU2010230311B9
(en)
|
2009-04-27 |
2012-09-20 |
Novartis Ag |
Composition and methods of use for therapeutic antibodies specific for the IL-12 receptore betal subunit
|
LT2424895T
(lt)
|
2009-04-27 |
2017-12-27 |
Novartis Ag |
Kompozicijos ir būdai, skirti raumenų augimo spartinimui
|
AR076284A1
(es)
|
2009-04-29 |
2011-06-01 |
Bayer Schering Pharma Ag |
Inmunoconjugados de antimesotelina y usos de los mismos
|
US20120263743A1
(en)
*
|
2009-04-30 |
2012-10-18 |
Cytos Biotechnology Ag |
Influenza hemagglutinin compositions and uses thereof
|
AU2010252939B2
(en)
|
2009-05-29 |
2014-06-26 |
Morphosys Ag |
A collection and methods for its use
|
WO2011021146A1
(en)
|
2009-08-20 |
2011-02-24 |
Pfizer Inc. |
Osteopontin antibodies
|
US20110082054A1
(en)
*
|
2009-09-14 |
2011-04-07 |
Dyax Corp. |
Libraries of genetic packages comprising novel hc cdr3 designs
|
US20110189183A1
(en)
|
2009-09-18 |
2011-08-04 |
Robert Anthony Williamson |
Antibodies against candida, collections thereof and methods of use
|
EP2501824A4
(de)
|
2009-11-17 |
2013-06-19 |
Janssen Biotech Inc |
Verbesserte proteinabscheidung auf bakterienmembranen
|
US8728985B2
(en)
|
2009-11-17 |
2014-05-20 |
Centocor Ortho Biotech Inc. |
Display of disulfide linked dimeric proteins in filamentous phage
|
DK2528944T3
(en)
|
2010-01-29 |
2015-09-14 |
Morphosys Ag |
Rodent combinatorial antibody libraries
|
CA2798432A1
(en)
|
2010-05-06 |
2011-11-10 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
|
WO2011138391A1
(en)
|
2010-05-06 |
2011-11-10 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
|
CN105734678B
(zh)
|
2010-07-16 |
2019-11-05 |
阿迪马布有限责任公司 |
合成多核苷酸文库
|
PT2606070T
(pt)
|
2010-08-20 |
2017-03-31 |
Novartis Ag |
Anticorpos para o recetor 3 do fator de crescimento epidérmico (her3)
|
MY177065A
(en)
|
2010-09-09 |
2020-09-03 |
Pfizer |
4-1bb binding molecules
|
MX2013003828A
(es)
|
2010-10-05 |
2013-06-28 |
Daiichi Sankyo Co Ltd |
Anticuerpo dirigido a la proteina lectina tipo inmunoglobulina de union a acido sialico-15 relacionada con osteoclastos.
|
AU2011331129B2
(en)
|
2010-11-19 |
2016-10-06 |
Morphosys Ag |
A collection and methods for its use
|
EP2655614B1
(de)
|
2010-12-22 |
2017-03-15 |
President and Fellows of Harvard College |
Kontinuierliche gerichtete evolution
|
JP2014526886A
(ja)
|
2011-07-15 |
2014-10-09 |
モルフォシス・アー・ゲー |
マクロファージ遊走阻止因子(mif)とd−ドーパクロームトートメラーゼ(d−dt)に交差反応性がある抗体
|
DK2768859T3
(en)
|
2011-10-19 |
2018-06-06 |
Morphosys Ag |
Antagonists of IL17C for the treatment of inflammatory diseases
|
MX362521B
(es)
|
2011-12-05 |
2019-01-22 |
Novartis Ag |
Anticuerpos para el receptor del factor de crecimiento epidermico 3 (her3).
|
SG11201402739YA
(en)
|
2011-12-05 |
2014-06-27 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
|
CA2861137C
(en)
*
|
2012-02-03 |
2022-03-22 |
The Governors Of The University Of Alberta |
Method of quantifying peptide-derivative libraries using phage display
|
IN2014KN02831A
(de)
|
2012-05-24 |
2015-05-08 |
Mountgate Group Ltd |
|
WO2014026905A1
(en)
|
2012-08-17 |
2014-02-20 |
Morphosys Ag |
Complex-specific antibodies and antibody fragments and its use
|
JOP20200308A1
(ar)
|
2012-09-07 |
2017-06-16 |
Novartis Ag |
جزيئات إرتباط il-18
|
MX2015005874A
(es)
|
2012-11-09 |
2015-09-10 |
Pfizer |
Anticuerpos especificos del factor de crecimiento b derivados de plaquetas y composiciones y usos de estos.
|
US9428577B2
(en)
|
2012-11-09 |
2016-08-30 |
Pfizer Inc. |
Platelet-derived growth factor B specific antibodies and compositions and uses thereof
|
EP2935324B1
(de)
|
2012-12-20 |
2019-10-23 |
MorphoSys AG |
Anti-staphylococcus-antikörper
|
CN105246916A
(zh)
|
2013-03-14 |
2016-01-13 |
诺华股份有限公司 |
针对notch 3的抗体
|
US9498543B2
(en)
|
2013-03-15 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
BR112015025622A2
(pt)
|
2013-04-12 |
2017-07-18 |
Morphosys Ag |
anticorpo ou fragmento de anticorpo isolado, composição farmacêutica, ácido nucleico, vetor, e célula hospedeira isolada
|
US20160060347A1
(en)
|
2013-04-17 |
2016-03-03 |
Morphosys Ag |
Antibodies targeting specifically human cxcr2
|
SG10201804439PA
(en)
|
2013-12-20 |
2018-06-28 |
Hutchinson Fred Cancer Res |
Tagged chimeric effector molecules and receptors thereof
|
EP3097196B1
(de)
|
2014-01-20 |
2019-09-11 |
President and Fellows of Harvard College |
Negativauswahl und stringenzmodulation in systemen der kontinuierlichen evolution
|
EP3116901B1
(de)
|
2014-03-14 |
2019-06-12 |
Immunocore Limited |
Tcr-bibliotheken
|
US10786578B2
(en)
|
2014-08-05 |
2020-09-29 |
Novartis Ag |
CKIT antibody drug conjugates
|
WO2016077052A2
(en)
|
2014-10-22 |
2016-05-19 |
President And Fellows Of Harvard College |
Evolution of proteases
|
CA2967188A1
(en)
|
2014-11-14 |
2016-05-19 |
Novartis Ag |
Antibody drug conjugates
|
EP3273994B1
(de)
|
2015-03-27 |
2021-12-01 |
University of Southern California |
Car-t-zelltherapie gegen lhr zur behandlung von soliden tumoren
|
WO2016168631A1
(en)
|
2015-04-17 |
2016-10-20 |
President And Fellows Of Harvard College |
Vector-based mutagenesis system
|
WO2016176652A2
(en)
|
2015-04-29 |
2016-11-03 |
Fred Hutchinson Cancer Research Center |
Modified stem cells and uses thereof
|
US20180355318A1
(en)
*
|
2015-04-29 |
2018-12-13 |
Fred Hutchinson Cancer Research Center |
Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
|
EP3095465A1
(de)
|
2015-05-19 |
2016-11-23 |
U3 Pharma GmbH |
Kombination von fgfr4-inhibitor und gallensäurekomplexbildner
|
US10711064B2
(en)
|
2015-06-04 |
2020-07-14 |
University Of Southern California |
Lym-1 and Lym-2 targeted CAR cell immunotherapy
|
MX2017015690A
(es)
|
2015-06-05 |
2018-07-06 |
Novartis Ag |
Anticuerpos dirigidos a la proteina morfogenetica osea 9 (bmp9) y metodos a partir de estos.
|
JOP20200312A1
(ar)
|
2015-06-26 |
2017-06-16 |
Novartis Ag |
الأجسام المضادة للعامل xi وطرق الاستخدام
|
WO2017015545A1
(en)
|
2015-07-22 |
2017-01-26 |
President And Fellows Of Harvard College |
Evolution of site-specific recombinases
|
US11524983B2
(en)
|
2015-07-23 |
2022-12-13 |
President And Fellows Of Harvard College |
Evolution of Bt toxins
|
US10612011B2
(en)
|
2015-07-30 |
2020-04-07 |
President And Fellows Of Harvard College |
Evolution of TALENs
|
DK3347377T3
(da)
|
2015-09-09 |
2021-05-10 |
Novartis Ag |
Tymisk stromal lymfopoietin (TSLP)-bindende antistoffer og fremgangsmåder til anvendelse af antistofferne
|
UY36889A
(es)
|
2015-09-09 |
2017-04-28 |
Novartis Ag |
Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
|
GB201516272D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
GB201516265D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
GB201516275D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
GB201516277D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR libraries
|
GB201516270D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
GB201516269D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
GB201516274D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
EP3352784A4
(de)
|
2015-09-23 |
2019-06-26 |
Cytoimmune Therapeutics, LLC |
Flt3-gerichtete car-zellen zur immuntherapie
|
JP2019511911A
(ja)
|
2016-02-17 |
2019-05-09 |
ノバルティス アーゲー |
Tgfベータ2抗体
|
CN108699143B
(zh)
|
2016-02-19 |
2021-11-09 |
莫佛塞斯公司 |
Il-17c的抗体
|
TW201802121A
(zh)
|
2016-05-25 |
2018-01-16 |
諾華公司 |
抗因子XI/XIa抗體之逆轉結合劑及其用途
|
US11254734B2
(en)
|
2016-11-14 |
2022-02-22 |
Morphosys Ag |
Fab molecules with a rodent hinge region and a non-rodent CH1 region
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
US11447809B2
(en)
|
2017-07-06 |
2022-09-20 |
President And Fellows Of Harvard College |
Evolution of tRNA synthetases
|
EP3444275A1
(de)
|
2017-08-16 |
2019-02-20 |
Exiris S.r.l. |
Monoklonaler antikörper anti-fgfr4
|
US11624130B2
(en)
|
2017-09-18 |
2023-04-11 |
President And Fellows Of Harvard College |
Continuous evolution for stabilized proteins
|
US11591385B2
(en)
|
2017-11-09 |
2023-02-28 |
Pinteon Therapeutics Inc. |
Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
|
CN111902427A
(zh)
|
2017-11-22 |
2020-11-06 |
诺华股份有限公司 |
抗因子XI/XIa抗体的逆转结合剂及其用途
|
EP3774926A1
(de)
|
2018-04-05 |
2021-02-17 |
Bio-Rad ABD Serotec GmbH |
Anzeigesysteme für proteine von interesse
|
CA3097253A1
(en)
|
2018-05-16 |
2019-11-21 |
Morphosys Ag |
Antibodies targeting glycoprotein vi
|
WO2019241649A1
(en)
|
2018-06-14 |
2019-12-19 |
President And Fellows Of Harvard College |
Evolution of cytidine deaminases
|
US20210277118A1
(en)
|
2018-06-21 |
2021-09-09 |
Daiichi Sankyo Company, Limited |
Compositions including cd3 antigen binding fragments and uses thereof
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
CA3132771A1
(en)
|
2019-03-14 |
2020-09-17 |
Morphosys Ag |
Antibodies targeting c5ar
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
PE20231093A1
(es)
|
2020-07-16 |
2023-07-18 |
Novartis Ag |
Anticuerpos anti-betacelulina, fragmentos de los mismos, y moleculas de union multiespecificas
|
EP4217391A1
(de)
|
2020-09-24 |
2023-08-02 |
MorphoSys AG |
Neue humane antikörper, die an humanes cd3-epsilon binden
|
EP4277664A1
(de)
|
2021-01-13 |
2023-11-22 |
Memorial Sloan Kettering Cancer Center |
Antikörper-pyrrolobenzodiazepinderivat-konjugat
|
TW202245844A
(zh)
|
2021-01-13 |
2022-12-01 |
紀念斯隆凱特琳癌症中心 |
抗dll3抗體-藥物結合物
|
JPWO2023032955A1
(de)
|
2021-08-31 |
2023-03-09 |
|
|
WO2023180346A1
(en)
|
2022-03-22 |
2023-09-28 |
Morphosys Ag |
Deimmunized antibodies specific for cd3
|
GB202204159D0
(en)
|
2022-03-24 |
2022-05-11 |
Heptares Therapeutics Ltd |
Antibodies
|